Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Trametinib (GSK1120212).

Robert Zeiser1, Hana Andrlová2, Frank Meiss3

  • 1Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany. robert.zeiser@uniklinik-freiburg.de.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|August 3, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

375
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
375
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany.

International journal of cancer·2026
Same author

Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2026
Same author

Donor lymphocyte infusions for recurrence of myeloid neoplasms after allogeneic hematopoietic cell transplantation in the era of hypomethylating agents and BCL2 inhibitors.

Annals of hematology·2026
Same author

A transcriptomic microglia taxonomy across mouse and human pathologies.

Nature immunology·2026
Same author

Clinical Development Programme of the Innovative Mesenchymal Stromal Cell Product MSC-FFM/MC0518 for Steroid-Refractory Acute Graft-Versus-Host Disease: Design of 2 Randomised Controlled Trials in Adult and Paediatric Patients.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie·2026
Same author

Symptom distress evolution over the first year after allogeneic stem cell transplantation - a prospective observational sub-study of the SMILe project.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same journal

Future Challenges of Molecular Imaging in Oncology.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

The Role of Molecular Imaging in Ion Beam Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Molecular Imaging in Photon Radiotherapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Advancements in Intraoperative Imaging for Enhanced Surgical Precision.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
See all related articles

Trametinib, a MEK inhibitor (mitogen-activated protein kinase/ERK kinase), shows promise in treating metastatic melanoma. Further trials will explore its role in other solid tumors, potentially combined with BRAF inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Mitogen-activated protein kinase (MEK) signaling pathways regulate crucial cellular functions like proliferation and survival.
  • MEK inhibition is a validated strategy for antineoplastic (anti-cancer) therapy.
  • Trametinib is a selective oral inhibitor of MEK1 and MEK2.

Purpose of the Study:

  • To review preclinical and clinical data for trametinib.
  • To present the mechanisms of action of trametinib.
  • To discuss the potential of trametinib in treating various solid tumors.

Main Methods:

  • Review of in vitro studies.
  • Analysis of preclinical data.
  • Evaluation of findings from clinical studies.
Keywords:
Kinase inhibitionMAPK/ERK Kinase (MEK)Small moleculesTrametinib

Related Experiment Videos

Main Results:

  • Trametinib is FDA-approved for metastatic melanoma in combination with a BRAF inhibitor.
  • Preclinical and clinical data support trametinib's efficacy.
  • Trametinib targets MEK1 and MEK2, key components of the MAPK/ERK pathway.

Conclusions:

  • Trametinib is an effective targeted therapy for certain cancers.
  • Future clinical trials are necessary to define trametinib's role in other solid tumors.
  • Combination therapy, particularly with BRAF inhibitors, may enhance trametinib's therapeutic potential.